Stay updated on EMPA Acute Heart Failure Improv Trial
Sign up to get notified when there's something new on the EMPA Acute Heart Failure Improv Trial page.

Latest updates to the EMPA Acute Heart Failure Improv Trial page
- Check7 days agoChange DetectedA new 'Locations' section appears with North Rhine-Westphalia as the study location. The page also removes the HHS Vulnerability Disclosure and the North Rhine-Westphalia Locations entry, and updates the revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; this appears to be a minor metadata/presentation update with no substantive changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange Detected- Deleted the funding lapse notice and operating status information from the study page. The notice previously informed users about government funding delays and directed them to cc.nih.gov and opm.gov for status updates.SummaryDifference0.4%

- Check57 days agoChange DetectedNo significant changes detected; any minor differences appear to be layout rendering rather than content updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check86 days agoChange DetectedAdded a government-operating-status notice and new version v3.2.0; removed old version v3.1.0.SummaryDifference4%

- Check93 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content, indicating a restructuring and possible narrowing of the domain coverage.SummaryDifference0.5%

Stay in the know with updates to EMPA Acute Heart Failure Improv Trial
Enter your email address, and we'll notify you when there's something new on the EMPA Acute Heart Failure Improv Trial page.